SCHEMBL6722608

SCHEMBL6722608

CS(=O)(=O)c1ccc(-c2nc(C(F)F)[nH]c2-c2cccnc2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.40
ALOX5 P09917 3/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
NTRK1 P04629 1/20 0.38
MAPK14 Q16539 3/20 0.37
BRAF P15056 1/20 0.36
NPY5R Q15761 1/20 0.36
PTGS1 P23219 3/20 0.36
ALDH1A1 P00352 2/20 0.35
CSNK1A1 P48729 1/20 0.35
CSNK1D P48730 1/20 0.35
CSNK1E P49674 1/20 0.35
MAPK11 Q15759 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CSNK1A1L Q8N752 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722081 0.88 ALDH1A1 (0.47) PTGS2ALOX5MAPK14PTGS1ALDH1A1
SCHEMBL6736522 0.87 PTGS2 (0.41) PTGS2ALOX5LMNAPOLBMAPK14
SCHEMBL6735431 0.87 LMNA (0.40) PTGS2ALOX5LMNAPOLBNTRK1
SCHEMBL6722071 0.85 MAPK14 (0.37) PTGS2ALOX5LMNAMAPK14PTGS1
SCHEMBL6723515 0.85 ALOX5 (0.40) PTGS2ALOX5MAPK14PTGS1ALDH1A1
SCHEMBL6730668 0.85 PTGS1 (0.40) PTGS2ALOX5MAPK14PTGS1ALDH1A1
SCHEMBL6719062 0.85 PTGS2 (0.38) PTGS2ALOX5MAPK14PTGS1ALDH1A1
SCHEMBL6723200 0.85 PTGS1 (0.48) PTGS2ALOX5MAPK14BRAFPTGS1
SCHEMBL6725894 0.84 MAPK14 (0.47) ALOX5MAPK14CSNK1DCSNK1E
SCHEMBL6723552 0.84 PTGS1 (0.39) PTGS2ALOX5MAPK14PTGS1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885ALOX5 108/4885LMNA 4037/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885ALOX5 79/4885LMNA 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.